Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dexcom Inc (DXCM)

Dexcom Inc (DXCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Reasons Investors Love DexCom (DXCM)

3 Reasons Investors Love DexCom (DXCM)

DXCM : 63.98 (+4.49%)
Q4 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

Q4 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

DXCM : 63.98 (+4.49%)
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

DXCM : 63.98 (+4.49%)
Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call...

DXCM : 63.98 (+4.49%)
2 Growth Stocks with All-Star Potential and 1 That Underwhelm

2 Growth Stocks with All-Star Potential and 1 That Underwhelm

TASK : 7.42 (+0.95%)
NX : 20.26 (+6.74%)
DXCM : 63.98 (+4.49%)
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know

Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know

OMCL : 38.28 (+1.81%)
PODD : 203.73 (+1.12%)
ALGN : 190.07 (+2.73%)
DXCM : 63.98 (+4.49%)
QDEL : 12.71 (+0.20%)
2 of Wall Street’s Favorite Stocks with Solid Fundamentals and 1 Facing Headwinds

2 of Wall Street’s Favorite Stocks with Solid Fundamentals and 1 Facing Headwinds

VEEV : 167.95 (+0.16%)
NVR : 7,000.92 (+4.44%)
DXCM : 63.98 (+4.49%)
2 Healthcare Stocks to Target This Week and 1 That Underwhelm

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

HIMS : 28.82 (+6.78%)
NVAX : 8.84 (+2.31%)
DXCM : 63.98 (+4.49%)
Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know

Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know

FTRE : 10.38 (+2.87%)
HUM : 205.14 (+2.18%)
PACB : 1.6900 (+3.68%)
ALHC : 21.22 (+1.92%)
DXCM : 63.98 (+4.49%)
Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy 1 , ...

DXCM : 63.98 (+4.49%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.